[1] Jemal A,Bray F,Center MM,et al. Global cancer statistics[J].CA Cancer J Clin,2011,61:69-90. [2] Parfitt JR,Miladinovic Z,Driman DK,et al. Increasing incidence of adenocarcinoma of the gastroesophageal junction and distal stomach in Canada-an epidemiological study from 1964-2002[J]. Can J Gastroenterol,2006,20:271-276. [3] Nashimoto A,Nakajima T,Furukawa H,et al. Randomized trial of adjuvant chemotherapy with mitomycin,fluorouracil,and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer: Japan clinical oncology group 9206-1[J]. J Clin Oncol,2003,21:2282-2287. [4] Siegel R,Ma JM,Zou ZH,et al. Cancer statistics,2014[J].CA Cancer J Clin,2014,64:9-29. [5] 孙益红,章真.胃癌//汤钊猷,蒋国梁.现代肿瘤学.3版.上海:复旦大学出版社,2012:887. [6] 李勇.我国胃癌研究的进展//李勇,范立侨.胃癌.北京:科学技术出版社,2010:16. [7] Stefano R,Luigi B,Francesca R,et al. Locally advanced gastric cancer: a new definition to standardize[J]. J Clin Pathol,2013,66:164-165. [8] Songun I,Putter H,Kranenbarg EM,et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol,2010,11:439-449. [9] Gebski V,Burmeister B,Smithers BM,et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis[J]. Lancet Oncol,2007,8:226-234. [10] Muratore A,Zorzi D,Bouzari H,et al. Asymptomatic colorectal cancer with un-resectable liver metastases:immediate colorectal resection or up-front systemic chemotherapy[J]? Ann Surg Oncol,2007,14:766-770. [11] Cunningham D,Allum WH,Stenning SP,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med,2006,355:11-20. [12] Ychou M,Boige V,Pignon JP,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol,2011,29:1715-1721. [13] Li H,Cao Y,Zhai L,et al. Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer[J]. J Clin Oncol,2010,28:Abstract 4042. [14] Ajani JA,Mansfield PF,Janjan N,et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma[J]. J Clin Oncol,2004,22:2774-2780. [15] Ajani JA,Mansfield PF,Crane CH,et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome[J]. J Clin Oncol,2005,23:1237-1244. [16] Ajani JA,Winter K,Okawara GS,et al. Phase Ⅱ trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma(RTOG 9904): quality of combined modality therapy and pathologic response[J]. J Clin Oncol,2006,24:3953-3958. [17] van Heijl M,van Lanschot JJ,Koppert LB,et al. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus(CROSS)[J]. BMC Surq,2008,26:21. [18] Pera M,Gallego R,Montagut C,et al. Phase Ⅱ trial of preoperative chemoradiotherapy with oxaliplatin,cisplatin,and 5-FU in locally advanced esophageal and gastric cancer[J]. Ann Oncol,2012,23:664-670. [19] Stahl M,Walz MK,Stuschke M,et al. Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol,2009,27:851-856. [20] Sakuramoto S,Sasako M,Yamaguchi T,et al. Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine[J]. N Engl J Med,2007,357:1810-1820. [21] Bang YJ,Kim YW,Yang HK,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC): a phase 3 open-label,randomised controlled trial[J]. Lancet,2012,379:315-321. [22] Sakamoto J,Paoletti X. Meta-analyses of randomized trials assessing the interest of postoperative adjuvant chemotherapy in gastric cancer[J]. J Clin Oncol,2008,26:Abstract 4543. [23] Macdonald JS,Smalley SR,Benedetti J,et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction[J]. N Engl J Med,2001,345:725-730. [24] Stephen RS,Jacqueline KB,Daniel GH,et al. Updated analysis of SWOG-directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J]. J Clin Oncol,2012,30:2327-2333. [25] Kim S,Lim DH,Lee J,et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach[J]. Int J Radiat Oncol Biol Phys,2005,63:1279-1285. [26] 王鑫,金晶,李晔雄,等.局部晚期胃癌术后预后因素分析及对术后辅助治疗意义探讨[J].中华放射肿瘤学杂志,2011,20:306-311. [27] Lee J,Lim DH,Kim S,et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol,2012,30:268-273. [28] 秦玉娥,周福祥,戴静,等.进展期胃癌根治术后放化疗与单纯化疗预后分析[J].中华放射肿瘤学杂志,2013,22:263-265. [29] 郭旗,黄维贤,崔溪溪,等.胃癌术后辅助放化疗与辅助化疗比较的荟萃分析[J].中华放射肿瘤学杂志,2013,22:433-437. [30] Zhu WG,Xua DF,Pu J,et al. A randomized,controlled,multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection[J]. Radiother Oncol,2012,104:361-366. [31] Dikken JL,van Sandick JW,Maurits-Swellengrebel HA,et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer(CRITICS)[J]. BMC Cancer,2011,11:329-336.
2014, Vol. 23 
